WO2010107702A1 - Treating alzheimer's disease and osteoporosis and reducing aging - Google Patents

Treating alzheimer's disease and osteoporosis and reducing aging Download PDF

Info

Publication number
WO2010107702A1
WO2010107702A1 PCT/US2010/027330 US2010027330W WO2010107702A1 WO 2010107702 A1 WO2010107702 A1 WO 2010107702A1 US 2010027330 W US2010027330 W US 2010027330W WO 2010107702 A1 WO2010107702 A1 WO 2010107702A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
serotonin
composition contains
aspirin
quantities
Prior art date
Application number
PCT/US2010/027330
Other languages
French (fr)
Inventor
Chien-Hung Chen
Original Assignee
Ipintl, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipintl, Llc filed Critical Ipintl, Llc
Priority to EP10753934.8A priority Critical patent/EP2408434A4/en
Priority to JP2012500854A priority patent/JP2012520883A/en
Priority to AU2010225923A priority patent/AU2010225923B2/en
Priority to CN2010800171927A priority patent/CN102395359A/en
Publication of WO2010107702A1 publication Critical patent/WO2010107702A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention features a method for treating Alzheimer's disease or osteoporosis by administering to a subject in need of the treatment a composition that includes (1) a first agent that can be an oxidative phosphorylation inhibitor, an ionophore, or an adenosine 5 '-monophosphate-activated protein kinase (AMPK) activator, (2) a second agent that possesses anti-inflammatory activity, and (3) a third agent that possesses or maintains serotonin activity.
  • oxidative phosphorylation inhibitor refers to a suitable agent that inhibits oxidative phosphorylation, such as oxidative phosphorylation uncouplers.
  • An ionophore is a lipid- soluble molecule capable of transporting an ion across the lipid bilayer of cell membranes.
  • An AMPK activator is an agent that activates AMPK to phosphorylate its substrates, e.g., acetyl-CoA carboxylase and malony 1-CoA decarboxylase.
  • the first agent include metformin (e.g., metformin chloride), phenformin, buformin, ephedrine, thyroxine, salicylanilide, and salicylic acid.
  • the second agent can be a suitable anti-inflammatory compound (e.g., non-steroidal anti-inflammatory compound).
  • the first agent can be an oxidative phosphorylation inhibitor, an ionophore, or an adenosine 5'-monophosphate-activated protein kinase (AMPK) activator.
  • the first agent can include, in addition to those described above, 4,6-dinitro-o-cresol, uncoupling proteins (e.g., UCPl, UCP2, or UCP3), carbonyl cyanide p-(trifluoromethoxy)phenyl- hydrazone, carbonyl cyanide m-chlorophenyl-hydrazone, C5 gene products, dinitrophenol (e.g., 2,4-dinitrophenol), efrapeptin (A23871), guanethidine, chlorpromazine, amytal, secobarbital, rotenone, progesterone, antimycin A, naphthoquinone, 8-hydroxyquinoline, carbon monoxide, cyanides, azides (e.g., NaN 3
  • serotonin reuptake inhibitors e.g., arylpyrrolidine compounds, phenylpiperazine compounds, benzylpiperidine compounds, piperidine compounds, tricyclic gamma-carbolines duloxetine compounds, pyrazinoquinoxaline compounds, pyridoindole compounds, piperidyindole compounds, milnacipran, citalopram, sertraline metabolite demethylsertraline, norfluoxetine, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapox
  • serotonin reuptake inhibitors e.g., arylpyrrolidine compounds, phenylpiperazine compounds, benzylpiperidine compounds, piperidine compounds, tricyclic gamma-carbolines duloxetine compounds,
  • a subject in need can be identified by a health care professional based on results from a suitable diagnostic method.
  • treating or “treatment” used herein refers to administering an above-described compositions to a subject, who has a disease mentioned above, a symptom of such a disease, or a predisposition towards such a disease, with the purpose of conferring a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the disease, the symptom of it, or the predisposition towards it.
  • reducing fatigue used herein refers to lessening, ameliorating, or relieving one or more symptoms of fatigue (e.g., low energy, poor endurance, and attention deficits) in a subject.
  • Reducing aging refers to lessening, ameliorating, or relieving the deleterious effects of aging (e.g., low vigor, memory loss, weakened vision or hearing, and joint pain) in a subject.
  • parenterally refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique.
  • acceptable vehicles and solvents that can be used are mannitol, water, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution.
  • fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5'- monophosphate-activated protein kinase activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

Description

Treating Alzheimer's Disease and Osteoporosis and Reducing Aging
CROSS REFERENCE TO RELATED APPLICATION
Pursuant to 35 U.S. C. § 119(e), this application claims priority to U.S. Provisional Application Serial No. 61/160,533, filed March 16, 2009, the contents of which are hereby incorporated by reference.
BACKGROUND
Alzheimer's disease is an age-related neurological disease characterized by memory loss and dementia. Osteoporosis, also an age-related disease, results in low bone mass and loss of bone tissue. There is a need to develop a new approach to treat these two age-related diseases or otherwise reduce aging.
SUMMARY
In one aspect, the present invention features a method for treating Alzheimer's disease or osteoporosis by administering to a subject in need of the treatment a composition that includes (1) a first agent that can be an oxidative phosphorylation inhibitor, an ionophore, or an adenosine 5 '-monophosphate-activated protein kinase (AMPK) activator, (2) a second agent that possesses anti-inflammatory activity, and (3) a third agent that possesses or maintains serotonin activity. The term "oxidative phosphorylation inhibitor" refers to a suitable agent that inhibits oxidative phosphorylation, such as oxidative phosphorylation uncouplers. An ionophore is a lipid- soluble molecule capable of transporting an ion across the lipid bilayer of cell membranes. An AMPK activator is an agent that activates AMPK to phosphorylate its substrates, e.g., acetyl-CoA carboxylase and malony 1-CoA decarboxylase. Examples of the first agent include metformin (e.g., metformin chloride), phenformin, buformin, ephedrine, thyroxine, salicylanilide, and salicylic acid. The second agent can be a suitable anti-inflammatory compound (e.g., non-steroidal anti-inflammatory compound). Examples include aspirin, diclofenac (e.g., diclofenac potassium or diclofenac sodium), ibuprofen (e.g., dexibuprofen or dexibuprofen lysine), indomethacin, acetaminophen, nimesulide, and a COX-2 inhibitor (e.g., a nitric oxide -based COX-2 inhibitor). The third agent can be a compound possessing or maintaining at least one of serotonin's activities and, when used in combination with the first and second agents, effectively treats one or more of the target diseases of this invention. Examples include serotonin (e.g., serotonin sulfate, a serotonin creatinine sulfate complex, or serotonin hydrochloride) and a serotonin re -uptake inhibitor. A preferred composition contains metformin hydrochloride, aspirin, and a serotonin creatinine sulfate complex. The three agents mentioned above can treat a target disease via biological mechanisms other than those described therein. For example, metformin may treat a target disease (e.g., osteoporosis) via a mechanism other than inhibiting oxidative phosphorylation or activating AMPK.
The composition described above can contain 5-5,000 mg (e.g., 5-3,000 mg, 5-1 ,500 mg, or 5-1 ,000 mg) of the first agent, 1-5,000 mg (e.g., 1 -3,000 mg, 1-1 ,000 mg, 1-500 mg, or 1 -100 mg) of the second agent, and 0.1 -1 ,000 mg (e.g., 0.1 -100 mg, 0.1-50 mg, or 0.1 -30 mg) of the third agent, or in quantities of the same ratio as that calculated based on the above amounts.
In another aspect, the present invention features a method for reducing aging or fatigue by administering the above-described composition to a subject in need of the treatment. In yet another aspect, this invention features a method for treating sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder by administering the above-described composition to a subject in need of the treatment.
Also within the scope of this invention is the use of the above-described composition for the manufacture of a medicament for any of the diseases and disorders mentioned above.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. DETAILED DESCRIPTION
Disclosed herein is use of a composition for treating various diseases/disorders, e.g., Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes at least three active agents which are described immediately below and also in US Patent Application Nos. 60/885,212 and 12/014,932.
The first agent can be an oxidative phosphorylation inhibitor, an ionophore, or an adenosine 5'-monophosphate-activated protein kinase (AMPK) activator. The first agent can include, in addition to those described above, 4,6-dinitro-o-cresol, uncoupling proteins (e.g., UCPl, UCP2, or UCP3), carbonyl cyanide p-(trifluoromethoxy)phenyl- hydrazone, carbonyl cyanide m-chlorophenyl-hydrazone, C5 gene products, dinitrophenol (e.g., 2,4-dinitrophenol), efrapeptin (A23871), guanethidine, chlorpromazine, amytal, secobarbital, rotenone, progesterone, antimycin A, naphthoquinone, 8-hydroxyquinoline, carbon monoxide, cyanides, azides (e.g., NaN3), dicoumarin, bilirubin, bile pigment, ephedrine, hydrogen sulfide, tetraiodothyronine, quercetin, 2,4-bis(p-chloroanilino)pyrimidine, glyceraldehyde-3-phosphate dehydrogenase, oligomycin, tributyltin chloride, aurovertin, rutamycin, venturicidin, mercurials, dicyclohexylcarbdiimide, Dio-9, m-chlorophenyl-hydrazone mesoxalonitrile, ionomycin, calcium ionophores (e.g., A23187, NMDA, CA 1001, or enniatin B), compounds that increase the Ca+ concentration in mitochondria (e.g., atractyloside, bongkrekic acid, thapsigargin, amino acid neurotransmitters, glutamate, N-methyl-D- aspartic acid, carbachol, ionophores, inducers of potassium depolarization), apoptogens (i.e., compounds that induce apoptosis), valinomycin, gramicidin, nonactin, nigericin, lasalocid, and monensin. The first agent can be an AMPK activator (e.g., metfomin or phenformin, buformin, 5'-aminoimidazole-4-carboxyamide-ribonucleoside, thienopyridones, resveratrol, nootkatone, thiazole, or adiponectin).
The second agent can include steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs. Examples of steroidal anti- inflammatory drugs include glucocorticoids, hydrocortisone, cortisone, beclomethasone, dipropionate, betamethasone, dexamethasone, prednisone, methylprednisolone, triamcinolone, fluocinolone acetonide, fludrocortisone, and beclometasone propionate. Examples of non-steroidal anti-inflammatory drugs (NSAIDs) include Al 83827, ABT963, aceclofenac, acemetacin, acetyl salicylic acid, AHRl 0037, alclofenac, alminoprofen, ampiroxicam, amtolmetin guacil, apazone, atliprofen methyl ester, AU8001, benoxaprofen, benzydamine flufenamate, bermoprofen, bezpiperylon, BF388, BF389, BIRL790, BMS347070, bromfenac, bucloxic acid, butibufen, BW755C, C53, C73, C85, carprofen, CBS1108, celecoxib, CHF2003, chlorobiphenyl, choline magnesium trisalicylate, CHX108, cimicoxib, cinnoxicam, clidanac, CLX1205, COX-2 inhibitors, CP331, CS502, CS706, D 1367, darbufelone, deracoxib, dexketoprofen, DFP, DFU, diflunisal, DP155, DRF4367, E5110, E6087, eltenac, ER34122, esflurbiprofen, etoricoxib, F025, felbinac ethyl, fenbufen, fenclofenac, fenclozic acid, fenclozine, fenoprofen, fentiazac, feprazone, fϊlenadol, flobufen, florifenine, flosulide, flubichin methanesulfonate, flufenamic acid, fluprofen, flurbiprofen, FPL62064, FRl 22047, FR123826, FR140423, FR188582, FS205397, furofenac, GR253035, GW406381, HAI105, HAI106, HCT2035, HCT6015, HGP12, HN3392, HP977, HX0835, HYAL AT2101, ibufenac, ibuproxam-beta-cyclodextrin, icodulinum, IDEA070, iguratimod, imrecoxib, indoprofen, IP751, isoxepac, isoxicam, KC764, ketoprofen, L652343, L745337, L748731, L752860, L761066, L768277, L776967, L783003, L784520, L791456, L804600, L818571, LAS33815, LAS34475, licofelone, LM 4108, lobuprofen, lornoxicam, lumiracoxib, mabuprofen, meclofenamic acid, meclofenamate sodium, mefenamic acid, meloxicam, mercaptoethylguanidine, mesoporphyrin, metoxibutropate, miroprofen, mofebutazone, mofezolac, MXl 094, nabumetone, naproxen sodium, naproxen-sodium/metoclopramide, NCXIlOl, NCX284, NCX285, NCX4016, NCX4215, NCX530, niflumic acid, nitric oxide-based NSAIDs (NitroMed, Lexington, MA), nitrofenac, nitroflurbiprofen, nitronaproxen, NS398, ocimum sanctum oil, ONO3144, orpanoxin, oxaprozin, oxindanac, oxpinac, oxycodone/ibuprofen, oxyphenbutazone, P10294, P54, P8892, pamicogrel, parcetasal, parecoxib, PD138387, PD145246, PD164387, pelubiprofen, pemedolac, phenylbutazone, pirazolac, piroxicam, piroxicam beta-cyclodextrin, piroxicam pivalate, pirprofen, pranoprofen, resveratrol, R- ketoprofen, R-ketorolac, rofecoxib, RP66364, RU43526, RU54808, RWJ63556, S19812, S2474, S33516, salicylsalicylic acid, satigrel, SC236, SC57666, SC58125, SC58451, SFPP, SKF 105809, SKF86002, sodium salicylate, sudoxicam, sulfasalazine, sulindac, suprofen, SVT2016, T3788, TA60, talmetacin, talnifiumate, tazofelone, tebufelone, tenidap, tenoxican, tepoxalin, tiaprofenic acid, tilmacoxib, tilnoprofen arbamel, tinoridine, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, trifiusal, tropesin, TY 10222, TYl 0246, TYl 0474, UR8962, ursolic acid, valdecoxib, WAY120739, WY28342, WY41770, ximoprofen, YS 134, zaltoprofen, zidometacin, and zomepirac. The third agent includes serotonin and its functional equivalents. The functional equivalents of serotonin include serotonin metabolites (e.g., 5-hydroxyindoleacetic acid), serotonin transporter inhibitors (e.g., paroxetine, fluoxetine, fenfluramine, fluvoxamine, sertraline, imipramine, and those disclosed in WO 03/00663), serotonin receptor 2c modulators (e.g., BVT933, DPCA37215, IK264, PNU22394, WAY161503, R- 1065, YM348, and those disclosed in U.S. Patent No. 3,914,250, WO 01/66548, WO 02/10169, WO 02/36596, WO 02/40456, WO 02/40457, WO 02/44152, WO 02/48124, WO 02/51844, and WO 03/033479), serotonin reuptake inhibitors (e.g., arylpyrrolidine compounds, phenylpiperazine compounds, benzylpiperidine compounds, piperidine compounds, tricyclic gamma-carbolines duloxetine compounds, pyrazinoquinoxaline compounds, pyridoindole compounds, piperidyindole compounds, milnacipran, citalopram, sertraline metabolite demethylsertraline, norfluoxetine, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine, trazodone, mirtazapine, fluoxetine, fluvoxamine, indalpine, indeloxazine, milnacipran, paroxetine, sertraline, sibutramine, zimeldine, trazodone hydrochloride, dexfenfluramine, and those disclosed in U.S. Patent No. 6,365,633, WO 01/27060, and WO 01/162341), serotonin and noradrenaline reuptake inhibitors (e.g., venlafaxine, venlafaxine metabolite O- desmethylvenlafaxine, clomipramine, and clomipramine metabolite desmethylclomipramine), serotonin IA receptor antagonists (e.g., arylpiperazine compounds, azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans, or buspirone), serotonin 2A receptor antagonists (e.g., MDL100907 and fananserin), serotonin 2B or 2C receptor antagonists (e.g., pirazino(aza)indole compounds or serotonergic compounds), serotonin 6 receptor antagonists (e.g., 5-halo-tryptamine compounds), serotonin 7 receptor antagonists (e.g., 5-halo-tryptamine compounds or quinoline compounds), serotonin dopamine antagonists (e.g., olanzapine and ziperasidone), monoamine re -uptake inhibitors (e.g., amides), pyridazinone aldose reductase inhibitors (e.g., pyridazinone compounds), serotonergic agents, stimulants of serotonin receptors (e.g., ergoloid mesylate or pergolide mesylate), stimulants of serotonin synthesis (e.g., vitamin Bl, vitamin B3, vitamin B6, biotin, S- adenosylmethionine, folic acid, ascorbic acid, magnesium, coenzyme QlO, or piracetam), or serotonin agonists (e.g., fenfluramine).
The first, second, and third agents can also be salts, prodrugs, or solvates of the above-described compounds. A salt can be formed between an anion and a positively charged group (e.g., amino) of an agent. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifiuoroacetate, acetate, chlorophenyoxyacetate, malate, tosylate, tartrate, fumarate, glutamate, glucuronate, lactate, glutarate, benzoate, embonate, glycolate, pamoate, aspartate, parachlorophenoxyisobutyrate, formate, succinate, cyclohexanecarboxylate, hexanoate, octonoate, decanoate, hexadecanoate, octodecanoate, benzenesulphonate, trimethoxybenzoate, paratoluenesulphonate, adamantanecarboxylate, glycoxylate, pyrrolidonecarboxylate, naphthalenesulphonate, 1-glucosephosphate, sulphite, dithionate, and maleate. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) of an agent. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. The agents also include salts containing quaternary nitrogen atoms. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of being transformed into active compounds. A solvate refers to a complex formed between an active compound and a pharmaceutically acceptable solvent. Examples of pharmaceutically acceptable solvents include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.
The three active agents mentioned above are known drugs and are readily available to the public. Some can be purchased from chemical companies, such as
Sigma- Aldrich, St. Louis, MO. Regimens for administering these drug compounds are well known and, if necessary, can be easily re-established.
In addition to the three required agents, the composition used in the methods of this invention can include one or more additional active ingredients. To practice the method of the present invention, an effective amount of the above- described composition can be administered to a subject in need parenterally, orally, buccally, nasally, topically, or rectally. "An effective amount" as used herein refers to the amount of each active agent required to confer a therapeutic effect on the subject, either alone or in combination with one or more other active agents. Effective doses will vary, as recognized by those skilled in the art, depending on the type or degree of the disorder to be treated; the subject's size, weight, age, and sex; the route of administration; the excipient usage; and the possible co-usage with another therapeutic treatment. The daily dose of the compositions described above can be 5- 5,000 mg (e.g., 10-2,500 or 10-3,000 mg) of the first agent, 1-5,000 mg (e.g., 2-1,000 or 2-3,000 mg) of the second agent, and 0.1-1,000 mg (e.g., 1-50 mg) of the third agent.
A subject in need can be identified by a health care professional based on results from a suitable diagnostic method. The term "treating" or "treatment" used herein refers to administering an above-described compositions to a subject, who has a disease mentioned above, a symptom of such a disease, or a predisposition towards such a disease, with the purpose of conferring a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the disease, the symptom of it, or the predisposition towards it. The term "reducing fatigue" used herein refers to lessening, ameliorating, or relieving one or more symptoms of fatigue (e.g., low energy, poor endurance, and attention deficits) in a subject. "Reducing aging" refers to lessening, ameliorating, or relieving the deleterious effects of aging (e.g., low vigor, memory loss, weakened vision or hearing, and joint pain) in a subject.
The composition described herein can include a pharmaceutically acceptable carrier to form a pharmaceutical composition. The carrier must be "acceptable" in the sense that it is compatible with the active ingredients of the composition (and preferably, capable of stabilizing the active ingredients) and not deleterious to the subject to be treated. Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical compositions described herein to a subject. A sterile injectable composition can be a solution or suspension in a non-toxic parenterally acceptable diluent or solvent. The term "parenterally" as used herein refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique. Among the acceptable vehicles and solvents that can be used are mannitol, water, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution. In addition, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides). Fatty acids, such as oleic acid and its glyceride derivatives, are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar dispersing agents. Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers, which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purpose of formulation. A composition for oral administration can be any orally acceptable dosage form including capsules, powders, tablets, emulsions and aqueous suspensions, dispersions, and solutions. In the case of tablets or capsules, commonly used carriers or diluents include lactose and corn starch. Lubricating agents, such as magnesium stearate, can be added. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
A nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation. For example, such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
A composition for topical administration can be prepared in the form of an ointment, a gel, a plaster, an emulsion, a lotion, a foam, a cream of a mixed phase or amphiphilic emulsion system (oil/water-water/oil mixed phase), a liposome, a transfersome, a paste, or a powder.
Any of the compositions described above can also be administered in the form of suppositories for rectal administration. It can also be designed so that the composition is released in the intestine. For example, the composition is confined in a solid sub-unit or a capsule compartment that has a matrix or a wall or a closure comprising an enteric polymer which dissolves or disperses at the pH of the small or large intestine to release the drug substance in the intestine. Suitable enteric polymers have been described above and also in U.S. Patent No. 5,705,189. A composition can be included in a drink or food product. Examples include tea
(e.g., a tea drink and the contents of a tea bag), soft drinks, juice (e.g., a fruit extract and a juice drink), milk, coffee, cookies, cereals, candies, and snack bars.
The compositions described above can be preliminarily screened for their efficacy in treating an above-described disease or disorder by an in vitro assay and then confirmed by animal experiments and clinical trials. Other methods will also be apparent to those of ordinary skill in the art.
Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All of the publications cited herein (including patents and patent applications) are incorporated by reference in their entirety.
OTHER EMBODIMENTS All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features. From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A method for treating a disease, comprising administrating to a subject in need thereof an effective amount of a composition containing: a first agent selected from the group consisting of an oxidative phosphorylation 5 inhibitor, an ionophore, and an adenosine 5'-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti- inflammatory activity; and a third agent that possesses or maintains serotonin activity; wherein the disease is Alzheimer's disease, osteoporosis, sleep apnea, erectile o dysfunction, McArdle disease, or a carbohydrate metabolism disorder.
2. The method of claim 1, wherein the first agent is metformin, phenformin, buformin, ephedrine, thyroxine, salicylanilide, or salicylic acid. 5
3. The method of claim 2, wherein the first agent is metformin hydrochloride.
4. The method of claim 1 , wherein the second agent is a non-steroidal antiinflammatory compound. 0
5. The method of claim 1 , wherein the second agent is aspirin, diclofenac, ibuprofen, indomethacin, acetaminophen, nimesulide, or a COX-2 inhibitor.
6. The method of claim 5, wherein the second agent is aspirin. 5
7. The method of claim 1, wherein the third agent is serotonin or a serotonin re -uptake inhibitor.
8. The method of claim 7, wherein the third agent is serotonin sulfate, a serotonin creatinine sulfate complex, or serotonin hydrochloride.
9. The method of claim 1, wherein the composition contains 5-5,000 mg of the first agent, 1-5,000 mg of the second agent, and 0.1-1,000 mg of the third agent; or in quantities of the same ratio.
10. The method of claim 9, wherein the composition contains 5-1,500 mg of the first agent, 1-1,000 mg of the second agent, and 0.1-100 mg of the third agent; or in quantities of the same ratio.
11. The method of claim 10, wherein the composition contains 5-1,000 mg of the first agent, 1-500 mg of the second agent, and 0.1-50 mg of the third agent; or in quantities of the same ratio.
12. The method of claim 1, wherein the composition contains metformin hydrochloride, aspirin, and a serotonin creatinine sulfate complex.
13. The method of claim 12, wherein the composition contains 5-5,000 mg of metformin hydrochloride, 1-5,000 mg of aspirin, and 0.1-1,000 mg of the serotonin creatinine sulfate complex; or in quantities of the same ratio.
14. The method of claim 13, wherein the composition contains 5-1,500 mg of metformin hydrochloride, 1-1,000 mg of aspirin, and 0.1-100 mg of the serotonin creatinine sulfate complex; or in quantities of the same ratio.
15. The method of claim 14, wherein the composition contains 5-1,000 mg of metformin hydrochloride, 1-500 mg of aspirin, and 0.1-50 mg of the serotonin creatinine sulfate complex; or in quantities of the same ratio.
16. The method of claim 1, wherein the composition further comprising a pharmaceutically acceptable carrier.
17. The method of claim 1, wherein the composition contains the first, second, and third agents as the only active ingredients.
18. The method of claim 1 , wherein the first agent is an AMPK activator.
19. The method of claim 18, wherein the composition contains the first, second, and third agents as the only active ingredients.
20 The method of claim 18, wherein the AMPK activator is selected from the group consisting of metformin, phenformin, buformin, 5'-aminoimidazole-4- carboxyamide-ribonucleoside, thienopyridones, resveratrol, nootkatone, thiazole, and adiponectin.
21. The method of claim 1 , wherein the first agent is an oxidative phosphorylation inhibitor or ionophore.
22. A method for reducing aging or fatigue, comprising administrating to a subject in need thereof an effective amount of a composition containing: a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses or maintains serotonin activity.
23. The method of claim 22, wherein the first agent is metformin, phenformin, buformin, ephedrine, thyroxine, salicylanilide, or salicylic acid.
24. The method of claim 23, wherein the first agent is metformin hydrochloride.
25. The method of claim 22, wherein the second agent is a non-steroidal anti- inflammatory compound.
26. The method of claim 22, wherein the second agent is aspirin, diclofenac, ibuprofen, indomethacin, acetaminophen, nimesulide, or a COX-2 inhibitor.
27. The method of claim 26, wherein the second agent is aspirin.
28. The method of claim 22, wherein the third agent is serotonin or a serotonin re -uptake inhibitor.
29. The method of claim 28, wherein the third agent is serotonin sulfate, a serotonin creatinine sulfate complex, or serotonin hydrochloride.
30. The method of claim 22, wherein the composition contains 5-5,000 mg of the first agent, 1-5,000 mg of the second agent, and 0.1-1,000 mg of the third agent; or in quantities of the same ratio.
31. The method of claim 30, wherein the composition contains 5-1,500 mg of the first agent, 1-1,000 mg of the second agent, and 0.1-100 mg of the third agent; or in quantities of the same ratio.
32. The method of claim 31, wherein the composition contains 5-1,000 mg of the first agent, 1-500 mg of the second agent, and 0.1-50 mg of the third agent; or in quantities of the same ratio.
33. The method of claim 22, wherein the composition contains metformin hydrochloride, aspirin, and a serotonin creatinine sulfate complex.
34. The method of claim 33, wherein the composition contains 5-5,000 mg of metformin hydrochloride, 1-5,000 mg of aspirin, and 0.1-1 ,000 mg of the serotonin creatinine sulfate complex; or in quantities of the same ratio.
35. The method of claim 34, wherein the composition contains 5-1,500 mg of metformin hydrochloride, 1-1,000 mg of aspirin, and 0.1-100 mg of the serotonin creatinine sulfate complex; or in quantities of the same ratio.
36. The method of claim 35, wherein the composition contains 5-1,000 mg of metformin hydrochloride, 1-500 mg of aspirin, and 0.1-50 mg the serotonin creatinine sulfate complex; or in quantities of the same ratio.
37. The method of claim 22, wherein the composition further comprising a pharmaceutically acceptable carrier.
38. The method of claim 22, wherein the composition contains the first, second, and third agents as the only active ingredients.
39. The method of claim 22, wherein the first agent is an AMPK activator.
40. The method of claim 39, wherein the composition contains the first, second, and third agents as the only active ingredients.
41. The method of claim 39, wherein the AMPK activator is selected from the group consisting of metformin, phenformin, buformin, 5'-aminoimidazole-4- carboxyamide-ribonucleoside, thienopyridones, resveratrol, nootkatone, thiazole, and adiponectin.
42. The method of claim 22, wherein the first agent is an oxidative phosphorylation inhibitor or ionophore.
PCT/US2010/027330 2009-03-16 2010-03-15 Treating alzheimer's disease and osteoporosis and reducing aging WO2010107702A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10753934.8A EP2408434A4 (en) 2009-03-16 2010-03-15 Treating alzheimer's disease and osteoporosis and reducing aging
JP2012500854A JP2012520883A (en) 2009-03-16 2010-03-15 Treatment of Alzheimer's disease and osteoporosis and reduction of aging
AU2010225923A AU2010225923B2 (en) 2009-03-16 2010-03-15 Treating Alzheimer's disease and osteoporosis and reducing aging
CN2010800171927A CN102395359A (en) 2009-03-16 2010-03-15 Treating alzheimer's disease and osteoporosis and reducing aging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16053309P 2009-03-16 2009-03-16
US61/160,533 2009-03-16

Publications (1)

Publication Number Publication Date
WO2010107702A1 true WO2010107702A1 (en) 2010-09-23

Family

ID=42731206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/027330 WO2010107702A1 (en) 2009-03-16 2010-03-15 Treating alzheimer's disease and osteoporosis and reducing aging

Country Status (6)

Country Link
US (1) US8377947B2 (en)
EP (1) EP2408434A4 (en)
JP (1) JP2012520883A (en)
CN (1) CN102395359A (en)
AU (1) AU2010225923B2 (en)
WO (1) WO2010107702A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2535393A4 (en) * 2010-02-12 2014-04-02 Oceans King Lighting Science Borosilicate luminescent material and preparing method thereof
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US20160030389A1 (en) * 2013-03-13 2016-02-04 Alevere Medical Corporation Use of indole compounds for fat reduction and skin and soft tissue tightening
AU2014238147B2 (en) 2013-03-15 2019-01-31 Mars, Incorporated Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting
CN118105365A (en) * 2013-03-15 2024-05-31 马斯公司 Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
WO2015061280A1 (en) 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
CN106102737B (en) 2013-10-22 2019-06-14 综合医院公司 Cromoglycic acid derivative and the correlation technique of imaging and treatment
KR101743960B1 (en) * 2015-07-06 2017-06-08 서울대학교산학협력단 G 19 Pharmaceutical composition for preventing treating or retarding Alzheimers disease or dementia comprising G protein-Coupled Receptor19 agonist as an active ingredient
CN109195589A (en) * 2016-03-07 2019-01-11 米托充制药公司 DNP the and DNP prodrug treatment of neuromuscular, neurodegeneration, autoimmune, developmental character, cerebral concussion, scheroma and/or metabolic disease
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
JP7202376B2 (en) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド Cromolyn sodium and ibuprofen powder formulation
CN113038944A (en) 2018-07-02 2021-06-25 通用医疗公司 Powdered preparation of cromolyn sodium and alpha-lactose
KR102145438B1 (en) * 2018-12-21 2020-08-18 연세대학교 산학협력단 A composition for predicting a risk of neurodegenerative diseases and a method for predicting neurodegenerative diseases using the same
WO2021029434A1 (en) * 2019-08-15 2021-02-18 賢 石井 Therapeutic agent for dropped head syndrome and thoracolumbar deformity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045621A1 (en) * 1998-05-15 2002-04-18 The University Of British Columbia Method and composition for modulating amyloidosis
US20040167114A1 (en) * 1999-06-23 2004-08-26 Henry Fliss Zinc ionophores as therapeutic agents
US20070142291A1 (en) * 2000-04-10 2007-06-21 Cedars-Sinai Medical Center Methods for treating irritable bowel syndrome
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070191351A1 (en) * 2006-01-05 2007-08-16 Cowen Neil M Salts of potassium atp channel openers and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
WO1987004618A1 (en) * 1986-01-30 1987-08-13 University Of Utah Treatment of bone loss
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5096712A (en) * 1990-03-06 1992-03-17 Interneuron Pharmaceuticals, Inc. Method for enhancing performance so as to improve vigor and decrease fatigue, confusion, tension, and anxiety
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
DE69520528T2 (en) * 1994-06-14 2001-09-27 Raffinerie Tirlemontoise, S.A. Use of a composition containing inulin or oligofructose as an anti-cancer agent
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO1997048391A2 (en) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US5776431A (en) * 1997-03-26 1998-07-07 Galat; Alexander Water-soluble aspirin composition
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
AU776162B2 (en) * 1999-04-29 2004-08-26 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
MXPA03001157A (en) * 2000-08-07 2004-02-17 Ranbaxy Signature Llc Liquid formulation of metformin.
AU2002230423A1 (en) * 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
US20020137787A1 (en) * 2001-03-21 2002-09-26 Geho W. Blair Prevention or treatment of complications related to non-insulin dependent diabetes mellitus or type 2 diabetes mellitus
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
AU2003251970A1 (en) * 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
AU2003249492A1 (en) * 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
US20050054731A1 (en) 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
KR20070027747A (en) * 2004-06-30 2007-03-09 콤비네이토릭스, 인코포레이티드 Methods and reagents for the treatment of metabolic disorders
US20060040980A1 (en) * 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
WO2006024492A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
JP4745764B2 (en) * 2004-09-09 2011-08-10 花王株式会社 AMPK activator
CA2581298A1 (en) * 2004-10-25 2006-05-04 Novartis Ag Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
CN101257897A (en) * 2005-07-07 2008-09-03 西特里斯药业公司 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2614664A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome
US20070054965A1 (en) * 2005-09-05 2007-03-08 Kao Corporation AMPK activating agent
WO2007047575A2 (en) * 2005-10-14 2007-04-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep-related breathing disorders
EP1979366A4 (en) * 2006-01-10 2011-05-25 Ruey J Yu N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
KR20080085213A (en) 2006-01-12 2008-09-23 노파르티스 아게 Combination of mtor inhibitor and antifolate compound
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
CN1947719A (en) * 2006-10-29 2007-04-18 广东医学院 Application of aspirin for preventing and treating osteoporosis
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045621A1 (en) * 1998-05-15 2002-04-18 The University Of British Columbia Method and composition for modulating amyloidosis
US20040167114A1 (en) * 1999-06-23 2004-08-26 Henry Fliss Zinc ionophores as therapeutic agents
US20070142291A1 (en) * 2000-04-10 2007-06-21 Cedars-Sinai Medical Center Methods for treating irritable bowel syndrome
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070191351A1 (en) * 2006-01-05 2007-08-16 Cowen Neil M Salts of potassium atp channel openers and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRECO ET AL.: "Leptin regulates Tau phosphorylation and Amyloid through AMPK in Neuronal Cells.", BIOCHEM BIOPHYS RES COMMUN., vol. 380, no. 1, February 2009 (2009-02-01), pages 98 - 104, XP025937058 *
See also references of EP2408434A4 *
SUDLOW ET AL.: "Cyclic AMP Levels, Adenylyl Cyclase Activity, and Their Stimulation by Serotonin Quantified in Intact Neurons.", J GEN PHYSIOL., vol. 110, no. 3, 1997, pages 243 - 255, XP055102480 *

Also Published As

Publication number Publication date
JP2012520883A (en) 2012-09-10
EP2408434A4 (en) 2013-11-27
US20100234295A1 (en) 2010-09-16
AU2010225923A1 (en) 2011-11-10
EP2408434A1 (en) 2012-01-25
AU2010225923B2 (en) 2016-10-27
CN102395359A (en) 2012-03-28
US8377947B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
US8377947B2 (en) Treating alzheimer's disease and osteoporosis and reducing aging
US8431552B2 (en) Composition for treating metabolic syndrome
US8367645B2 (en) Compositions and methods for treating hyperproliferative diseases
AU2014200497A1 (en) Novel Composition for Treating Metabolic Syndrome
AU2015201896B2 (en) Novel Compositions and Methods for Treating Hyperproliferative Diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080017192.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10753934

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2012500854

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010753934

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010225923

Country of ref document: AU

Date of ref document: 20100315

Kind code of ref document: A